Bortezomib before and after high-dose therapy in transplant-eligible patients with newly diagnosed multiple myeloma: Long-term overall survival after more than 10 years of follow-up from the phase III HOVON-65/GMMG-HD4 trial.

Saved in:
Bibliographic Details
Title: Bortezomib before and after high-dose therapy in transplant-eligible patients with newly diagnosed multiple myeloma: Long-term overall survival after more than 10 years of follow-up from the phase III HOVON-65/GMMG-HD4 trial.
Authors: Mai EK; Heidelberg Myeloma Center, Department of Internal Medicine V, Heidelberg University Hospital and Medical Faculty Heidelberg Heidelberg University Heidelberg Germany., Nogai A; Medical Clinic for Hematology Oncology and Tumor Immunology, Charité Berlin Berlin Germany., Lokhorst HM; Department of Hematology VU University Medical Center Amsterdam The Netherlands., van der Holt B; HOVON, Rotterdam, The Netherlands and Department of Hematology Erasmus MC Cancer Institute Rotterdam The Netherlands., Zweegman S; Department of Hematology VU University Medical Center, Cancer Center Amsterdam Amsterdam The Netherlands., Weisel KC; Medical Clinic and Polyclinic II University Hospital Hamburg-Eppendorf Hamburg Germany., Croockewit S; Department of Hematology Radboud University Medical Center Nijmegen The Netherlands., Jauch A; Institute of Human Genetics Medical Faculty Heidelberg, University of Heidelberg Heidelberg Germany., Hillengass J; Department of Medicine Roswell Park Comprehensive Cancer Center Buffalo New York USA., Stevens-Kroef M; Laboratorium Tumor Genetica Radboud University Medical Centre Nijmegen The Netherlands., Raab MS; Heidelberg Myeloma Center, Department of Internal Medicine V, Heidelberg University Hospital and Medical Faculty Heidelberg Heidelberg University Heidelberg Germany., Broijl A; Department of Hematology Erasmus MC Cancer Institute Rotterdam The Netherlands., Bos GMJ; Department of Internal Medicine University Hospital Maastricht Maastricht The Netherlands., Brossart P; Internal Medicine III, Oncology, Hematology and Rheumatology University Hospital Bonn Bonn Germany., Ypma P; Department of Hematology Haga Hospital The Hague The Netherlands., Hanoun C; Department of Hematology University Hospital Essen Essen Germany., Bertsch U; Heidelberg Myeloma Center, Department of Internal Medicine V, Heidelberg University Hospital and Medical Faculty Heidelberg Heidelberg University Heidelberg Germany., Hielscher T; Division of Biostatistics German Cancer Research Center (DKFZ) Heidelberg Heidelberg Germany., Salwender HJ; Department of Hematology and Oncology Asklepios Hospital Hamburg Altona Hamburg Germany., Scheid C; Department I of Internal Medicine and Center of Integrated Oncology Cologne Bonn University of Cologne Cologne Germany., Goldschmidt H; Heidelberg Myeloma Center, Department of Internal Medicine V, Heidelberg University Hospital and Medical Faculty Heidelberg Heidelberg University Heidelberg Germany.; National Center for Tumor Diseases (NCT) Heidelberg University Hospital Heidelberg Germany., Sonneveld P; Department of Hematology Erasmus MC Cancer Institute Rotterdam The Netherlands.
Source: HemaSphere [Hemasphere] 2024 Nov 20; Vol. 8 (11), pp. e70052. Date of Electronic Publication: 2024 Nov 20 (Print Publication: 2024).
Publication Type: Journal Article
Journal Info: Publisher: Wiley Country of Publication: United States NLM ID: 101740619 Publication Model: eCollection Cited Medium: Internet ISSN: 2572-9241 (Electronic) Linking ISSN: 25729241 NLM ISO Abbreviation: Hemasphere Subsets: PubMed not MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:2572-9241
DOI:10.1002/hem3.70052